Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy consists of a topical corticosteroid and salicylic acid, primarily used for the treatment of mild to moderate psoriasis. Corticosteroids function as anti-inflammatory, antiproliferative, and immunosuppressive agents by binding to the glucocorticoid receptor, which helps reduce the erythema and swelling associated with psoriatic plaques. Salicylic acid acts as a keratolytic agent, softening and facilitating the shedding of the stratum corneum. This action helps remove the characteristic scales of psoriasis and enhances the skin penetration of the co-administered corticosteroid. This specific combination was evaluated by Assiut University in a clinical trial (NCT03443323) comparing its efficacy against climatotherapy at the Red Sea (Hurghada) in patients with psoriasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on corticosteroids + salicylic acid.